Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
September 21, 2023
The politics of antimicrobial resistance (AMR) has changed substantially since we launched the first CGD working group on AMR in 2007. There is now much more awareness about the need to act, even if global solutions have not yet been implemented. Countries including the UK, Canada, and Japan have an...
REPORTS
September 20, 2023
In our final working group report, we outline the principles of a Grand Bargain that we believe all stakeholders can and should sign up to during the UN General Assembly's High-Level Meeting on antimicrobial resistance in 2024. Explore our recommendations on increasing the availability of critically...
CGD NOTES
December 14, 2022
Ensuring rapid and equitable access to effective oral COVID-19 therapies is essential to reducing health disparities from COVID-19 and building a better response system for future epidemics and pandemics. A multipronged strategy for medical countermeasures must include antivirals, monoclonal antibod...
CGD NOTES
March 03, 2022
The COVID-19 pandemic has transformed the global vaccine manufacturing landscape, with capacity more than doubling in the past 18 months. Before the pandemic, manufacturers produced an estimated total of five billion vaccine doses each year. In 2021, manufacturers produced 12 billion doses of C...
Blog Post
February 15, 2022
Last week, the European Union and its member states placed a “European global health strategy” at the top of their shared agenda. And as part of the EU-Africa summit this week in Brussels, the EU is highlighting its support for regional manufacturing of COVID-19 vaccine via the African Union’s Partn...
Blog Post
December 09, 2021
Antibiotic resistance (AMR) is not a new problem. However, the global community has been slow to implement recommended policy measures and achieve systemic change. CGD will launch a working group on antimicrobial resistance—seeking to improve antibiotic access and R&D in low- and middle-inc...
Blog Post
October 21, 2021
Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blogs proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world’s vac...
Blog Post
May 25, 2021
A lot of recent discussions focus on how to expand COVID-19 vaccine manufacturing capacity in low- and middle-income countries (LMICs). The conversations highlight the importance of technology transfer and the capability of the tech transfer receiving sites (the facilities in these countries that wo...
Blog Post
May 17, 2021
Today we joined colleagues from CSIS, Duke University, and the COVID Collective in an open letter to the Biden Administration and US Congress with a clear message: to hasten the end of the COVID-19 global pandemic, American leadership is required to ensure universal global access to high-quality and...
Blog Post
March 26, 2021
Safe and efficacious vaccines are our best tools for defeating COVID-19. An unprecedented research and development effort has led to 12 vaccines with full or limited use emergency authorizations globally, but vaccinating everyone in the world as quickly as possible will require additional production...